June 26, 2017. This is no joke. The Congressional Budget Office’s report only makes it clearer that the Senate health bill will not result in better health care for Americans.
Read More »We’re Speaking Out on Health Issues
NCHR scientists and health policy experts provide written and oral statements on a wide range of topics.
Here are many of the ways we have been Speaking Out on Health Policy Issues for the last few years. Whether the topic is legislation intended to cure diseases, proposed bans on BPA or other chemicals that disrupt your hormones, the importance of including women, people of color, and patients over 65 in clinical trials, or many other topics, you’ll gain a better understanding of our evidence-based analyses by reading these letters, statements, and testimony.
Here are the ways we have been Speaking out on Medical Treatments and Products, such as prescription drugs and medical devices that the FDA is considering approving, or is considering taking off the market because of serious risks. Whether the topic is Chantix, Addyi, Yaz, Essure, or medical products you’ve never heard of, you can find out more about what is known and not known about the safety and effectiveness of a wide range of products by looking through this section of our website.
NCHR Statement on the Better Care Reconciliation Act of 2017
June 25, 2017. The Better Care Reconciliation Act of 2017 will result in much worse, not better, health care for Americans.
Read More »NCHR Comment on the USPSTF’s Draft Recommendations for Adolescent Idiopathic Scoliosis: Screening
June 22, 2017. We agree with the USPSTF’s assessment that there is inadequate evidence to support screening for adolescent idiopathic scoliosis. However, we are concerned that the change of grade from a “D” to “I” will be interpreted as if there is now more evidence to support screening instead of less confidence in the data surrounding its use.
Read More »NCHR Testimony at FDA Meeting on Pediatric Cancer Drugs
At the FDA Advisory Committee meeting, Dr. Megan Polanin of the National Center for Health Research expressed concerns about inadequate evidence regarding the safety and effectiveness of drugs for rare pediatric cancers, pointing out that it is better to provide experimental drugs for free in a clinical trial rather than approving those drugs based on inadequate preliminary evidence with the knowledge that they will be unaffordable because insurance companies will not pay for drugs that are not proven to work.
Read More »NCHR Testimony to FDA on Victoza to Prevent Cardiovascular Events
June 20 2017: Dr. Stephanie Fox-Rawlings of the National Center for Health Research told the FDA Advisory Committee that Victoza shouldn’t be approved to prevent heart problems in patients with type 2 diabetes unless better research is done on American patients to prove it works for them.
Read More »